EFMC-ISMC 2021

XXVI EFMC International Symposium on Medicinal Chemistry

 Virtual Event    August 29-September 2, 2021

EFMC Award Lectures

Prof. Ad P. IJZERMAN
The Nauta Pharmacochemistry Award for Medicinal Chemistry and Chemical Biology
Award Lecture
Partial Agonism in the Picture (AL001)
Dr Malin LEMURELL
The UCB-Ehrlich Award for Excellence in Medicinal Chemistry
Award Lecture
Experiences & Future Direction for Medicinal Chemistry in Cardiovascular, Renal and Metabolism Diseases (AL002)
Prof. Gisbert SCHNEIDER
The Prous Institute - Overton and Meyer Award for New technologies in Drug Discovery
Award Lecture
De Novo Drug Design with Machine Intelligence (AL003)

Prize Lectures

Dr Niall ANDERSON
The 2021 EFMC Prize for a Young Medicinal Chemist in Industry
Integrin Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis (PR003)
Prof. Yimon AYE
The 2020 EFMC Prize for a Young Medicinal Chemist in Academia
Within Our Control? Illuminating How Ephemeral Electrophiles Rewire Cell Decision-Making Processes (PR002)
Dr Giuseppe CECERE
The 2020 EFMC Prize for a Young Medicinal Chemist in Industry
Discovery of Potent Selective GABAA Alpha5 Positive Allosteric Modulators (PAMs) for the treatment of neurological disorders (PR001)
Dr Nir LONDON
The 2021 EFMC Prize for a Young Medicinal Chemist in Academia
COVID Moonshot – Crowdsourcing a Covid-19 Cure (PR004)
Dr John E. MACOR
The IUPAC-Richter Prize Lecture
The Discovery of Relpax® and Nurtec ODT® - Two Different Treatments for Migraine Headaches (PR005)
Prof. Stephan A. SIEBER
The Klaus Grohe Award Lecture
Chemical-Proteomic Strategies to Fight Multiresistant Bacteria (AL004)

Plenary Lectures

Prof. Phil BARAN
Translational Chemistry (PL003)
Dr Karin BRINER
Opening Lecture
Creating the Next Generation of Therapeutics - Medicinal Chemistry Unleashed (PL001)
Dr Jean-Paul CLOZEL
Medicinal Chemistry: More than Ever (PL002)
Prof. Stefan KNAPP
Targeting Protein Scaffolding Function in Kinases (PL004)
 
 

Invited Speakers

Dr Stellios ARSENIYADIS
Innovative DNA-based Asymmetric Catalysis (LE033)
Prof. Andreas BENDER
Artificial Intelligence in Chemical Biology and Drug Discovery - Data, Applications, and Illusions (LE059)
Prof. Gonçalo BERNARDES
Translational Chemical Biology (LE001)
Prof. Erem BILENSOY
Omics-Based Development of Nanomedicines for Safe and Effective Drug Delivery in Cancer (LE077)
Prof. Rebecca BULLER
Utilization of Fe/α-Ketoglutarate-Dependent Enzymes for Stereocontrolled Functionalization (LE098)
Prof. Erick M. CARREIRA
Recent Developments in Strategies and Tactics Towards Complex Secondary Metabolites (LE032)
Dr Paola CASTALDI
Mechanistic Insights of a CDK9 Inhibitor via Orthogonal Proteomics Methods (LE092)
Dr Grace CHUANG
Discovery of Aficamten (CK-274): A Novel, Small Molecule, Cardiac Myosin Inhibitor for the Potential Treatment of Hypertrophic Cardiomyopathies (HCM) (LE022)
Prof. Bernd CLEMENT
New Examples for N-Hydroxyamidine Prodrugs (LE085)
Prof. Leroy CRONIN
Universal Synthesis Machines and Chemputation (LE045)
Dr Eva CUNHA
Structure Based Drug Discovery Targeting Helicobacter Pylori, Using Cryo-EM (LE020)
Dr Werngard CZECHTIZKY
Inhaled New Modalities in Respiratory Disease: Past, Present, Future (LE048)
Dr Mike DAWSON
Therapies for Gram-Negative Bacterial Infections: New Approaches and Further Generations of Existing Series (LE063)
Dr Sheng DING
A Chemical Approach to Controlling Cell Fate (LE040)
Prof. Joerg DISTLER
Novel Molecular Targets for the Treatment of Fibrosis (LE088)
Dr Ola ENGKVIST
Progress and Limitations in Exploring the Chemical Space with AI (LE047)
Dr Montse ERRA SOLA
Discovery of Novel Inhaled PI3Kd Inhibitor by Lung Retention Optimisation (LE049)
Dr Niyi FADEYI
Mapping Cell-Cell Interactions in Tumor Microenvironment via Photocatalytic Proximity Labeling (LE014)
Dr Romain GOSMINI
Discovery of GLPG1205, a First in Class GPR84 Antagonist in Phase II Clinical Trial (LE089)
Dr David HARDICK
Drugging RNA Modifying Enzymes - METTL3 Inhibitors (LE068)
Prof. Amanda HARGROVE
Modulating Viral RNAS with Amiloride Small Molecules (LE070)
Dr Gerhard HESSLER
Navigating Chemical Space by Artificial Intelligence (LE061)
Prof. Donald HILVERT
Reprogramming Nonribosomal Peptide Biosynthesis (LE096)
Dr Kristiina HUTTUNEN
Targeted (Pro)Drugs for Improved Treatment of Brain Tumors (LE087)
Dr Anne IMBERTY
Lectins from Pathogens: From Structural Glycobiology to Antiadhesive Strategies (LE057)
Prof. Klavs F. JENSEN
AI Assisted and Automated Chemical Synthesis (LE044)
Dr Tim JONCKERS
Discovery of a Novel Class of Small Molecule Dengue Virus Inhibitors (LE036)
Dr Markus KLEIN
Structure-Based Optimization and Synthesis of M3258, a Potent and Selective Inhibitor of the Immunoproteasome Subunit LMP7 (beta5i) Demonstrating Strong Efficacy in Multiple Myeloma Models (LE101)
Dr Teodoro LAINO
AI in the Lab: Automating Chemical Synthesis. Where Next From Here? (LE046)
Dr Sergio MALLART
Identification of Potent and Long Acting Single-Chain Peptide Mimetics of Human Relaxin-2 for Cardiovascular Diseases (LE021)
Dr Muthiah MANOHARAN
Nucleic Acids as Household Medicine: Living in The World of RNA Therapeutics (LE076)
Dr Patrizio MATTEI
Tethered Macrocyclic Peptides, a Novel Antibiotic Class Targeting Acinetobacter Baumannii (LE064)
Dr Daniel MEIBOM
Neladenoson Bialanate Hydrochloride: a Prodrug Exploration of a Partial Adenosine A1 Agonist (LE086)
Prof. Marko D. MIHOVILOVIC
Flavoenzyme Biocatalysis in Bioorganic and Medicinal Chemistry - Challenges and Opportunities (LE097)
Prof. Barbara MONTI
Microglia in Neuroinflammation: an Intriguing Target towards Neuroprotection and Neuroregeneration (LE009)
Dr Herbert NAR
Allosteric Regulation of GTP Cyclohydrolase I (LE018)
Prof. Dario NERI
Antibody-Drug Conjugates (ADC) and Small Molecule-Drug Conjugates (SMDC): a Comparative Evaluation (LE075)
Dr Gary NEWTON
MAP4K4 Inhibitors For The Suppression Of Cardiac Muscle Cell Death (LE023)
Prof. Ulf NILSSON
Design, Synthesis, and Development of Lectin Ligand Mimetics (LE056)
Dr Valle PALOMO
Sensing Enzymatic Activity with Quantum Dots in Patient-Derived Neurodegenerative Disease Models (LE003)
Prof. Maria-Jesus PÉREZ-PÉREZ
Antivirals Against Chikungunya Virus: Analyzing the Current Situation to Identify New Opportunities (LE037)
Dr Jennifer PETTER
Targeting RNA With Drug-Like Small Molecules (LE067)
Dr Jonathan PHILLIPS
Introduction to Preclinical Inhaled Drug Dosing and its Application to Measure the Therapeutic Index of Inhaled Steroids (LE050)
Prof. Paola PICOTTI
Proteomes in 3D (LE093)
Prof. Tracey PIRALI
Magic in the Moonlight: Our Contribution to the Development of IDO1 Inhibitors for Cancer Immunotherapy (LE102)
Prof. Colin POUTON
Potential of Stem Cell Technology in Discovery of Drugs for Neurodegenerative Diseases (LE043)
Dr Xiangbing QI
Molecular Glue Design for Targeted Cancer Therapy (LE006)
Dr Christoph RADEMACHER
C-type Lectin Receptors as Drug Targets (LE055)
Prof. Daniel RAUH
Targeting Cancer (LE100)
Prof. Jarkko RAUTIO
Prodrug Strategies in Medicinal Chemistry (LE084)
Dr Judith REEKS
The Role of Cryo-EM in Fragment-Based Drug Discovery (LE019)
Prof. Pablo RIVERA FUENTES
Chemical Tools to Study Redox Biology (LE002)
Prof. Angela RUSSELL
Discovery of Small Molecules to Manipulate Cell Fate in vivo: Towards New Therapies for Degenerative Diseases (LE041)
Dr Nadine SCHNEIDER
Augmenting Drug Hunters with Generative Chemistry Models (LE060)
Dr Stacey SOUTHALL
Cryo-EM in GPCR Structure Based Drug Discovery (LE017)
Dr Wiktor SZYMANSKI
Photopharmacology: Towards Light-Controlled Therapy (LE013)
Dr Thomas THUM
Development of Non-Coding RNA Based Next-Generation Heart Failure Therapeutics (LE024)
Dr Mario VAN DER STELT
Chemical Probes to Study Lipid Signaling (LE029)
Prof. Jan VAN MAARSEVEEN
Scaffold-Assisted Peptide Cyclizations: Towards Protein Mimics (LE034)
Prof. Paul WORKMAN
Chemical Probes to Explore Cancer Biology and Validate Drug Targets (LE028)
Prof. Bernhard WÜNSCH
Development of Fluorinated PET Tracers for Imaging of α1 Receptors in the Brain (LE010)
Prof. Shengyong YANG
Discovery of New SARS-COV-2 MPRO Inhibitors With Potent in vitro and In vivo Antiviral Activity (LE007)
Prof. Jian ZHANG
Along the Allostery Stream: Recent Advances in Computational Methods for Allosteric Drug Discovery (LE005)

First Time Disclosures

Dr Simona COTESTA
Discovery of JDQ443 a Structurally Unique, Highly Potent, Selective and Orally Bioavailable KRASG12C Covalent Inhibitor (LE054)
Mr Kevin DACK
Discovery of an Oral, RO5 Compliant, Interleukin 17a Protein-Protein Interaction Modulator for the Treatment of Psoriasis and other Inflammatory Diseases (LE052)
Dr Thomas FUCHSS
Insights to the Discovery and Design of Ataxia Telangiectasia Mutated (ATM) Kinase inhibitors M3541 and M4076 with Strong Anti-tumor Efficacy in Combination Therapy Approaches (LE053)
Dr Jörg KLEY
First Time Disclosure of BI 1265162, an ENaC Inhibitor for the Treatment of Cystic Fibrosis (LE026)
Dr Magnus NILSSON
Discovery of the Clinical Candidate AZD4604, a Potent and Selective Janus Kinase 1 Inhibitor, as an Inhaled Treatment for Respiratory Disease (LE027)
Dr Susanne ROEHRIG
Design and Preclinical Characterization Program Towards BAY 2433334, an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders (LE025)

Oral Communications

Prof. Carolina H. ANDRADE
Artificial Intelligence for Emerging and Neglected Diseases Drug Discovery (LE038)
Dr Andrea ASTOLFI
Small Molecule Degradeers Targeting Folding Intermediates: the Prion Protein Case Study (LE012)
Mr André CAMPANICO
Azaaurones as Novel Chemotypes Against Mycobacterium Tuberculosis: SAR ADME Profiling and Photo-Switching Properties (LE015)
Ms Emma CAMPBELL
Splice-Switching Small Molecules as Inducers of Apoptosis (LE069)
Ms Aline CARREL
Synthesis of New Building Blocks from the Chemical Universe Database GDB (LE035)
Dr Pooja DESHMUKH
Generative Recurrent Neural Networks (RNN) for de novo Drug Design (LE062)
Ms Radhia EL PHIL
A Novel Bacterial Three-Hybrid System for Target Identification in Bacteria (LE094)
Ms Rita FÉLIX
Quenched Activity-based Probes as New Chemical Tools to Analyse Resistance to Antibiotics (LE031)
Dr Christian FISCHER
Discovery of MRK-740, a First-in-class, Potent, Selective and Cell Active PRDM9 Chemical Probe (LE030)
Dr Stefanie FLOHR
LNP023: Discovery and Synthesis of a First-In-Class, Oral Factor B Inhibitor for Treatment of Rare Renal and Hematological Diseases (LE074)
Prof. Evripidis GAVATHIOTIS
Targeting Oncogenic BRAF Using a Novel Allosteric Site (LE072)
Dr Elena GOMEZ
Discovery of LAS200019, a Novel Topical Jak Inhibitor for the Treatment of Inflammatory Skin Diseases (LE083)
Mr Salvador GUARDIOLA
Target-Templated de novo Design of Drug-like Cyclic Peptides: PD-1/PD-L1 Inhibitors (LE082)
Dr Rachel HEVEY
Development of Glycomimetic Collectin-11 Antagonists to Reduce Complement-Mediated Ischemia-Reperfusion Injuries (LE058)
Prof. Anna K. H. HIRSCH
Discovery of Submicromolar Inhibitors of the Virulence Factor LASB from Pseudomonas Aeruginosa Using Rational Design (LE065)
Dr Laia JOSA CULLERE
A Phenotypic Screen Identifies a Small Molecule that Induces Differentiation of AML Cells in vitro and Shows Anti-Tumour Effects in vivo (LE080)
Ms Tanya KELLEY
Design and Optimization of a First-in-class NACK Inhibitor: A Novel Path to Notch Inhibition (LE103)
Prof. Enza LACIVITA
Boosting the Resolution of Inflammation Through Formyl Peptide Receptor 2 (FPR2) Agonists as a Novel Strategy in Neuroinflammation-associated Central Nervous System Disorders (LE011)
Prof. Stefan LAUFER
Discovery and Development of a Mkk-4 Inhibitors to Increase Liver Regeneration (LE071)
Dr Marco LOLLI
Innovative Dihydroorotate Dehydrogenase Clinical Ready Inhibitors as Pan-Coronavirus Antivirals: Targeting the Unexpected with Innovation (LE039)
Dr Laia MIRET CASALS
Furan-Oxidation Mediated Technology: from in vitro Analysis of Protein-Protein Interactions to GPCR-Ligand Interactions on Live Cells (LE073)
Dr Leila MOTIEI
Pattern-generating Fluorescent Molecular Probes for Chemical Biology (LE004)
Ms Vanesa NOZAL GARCIA
Isoform-selective TAU Tubuline Kinase 1 Inhibitors Reduce TDP-43 Hyperphosphorylation: a New Hope in the Treatment of TDP-43 Proteinopathies (LE081)
Dr Adeline PALISSE
Discovery of the Highly Potent and Selective S1P2 Antagonist GLPG2938, a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis (LE091)
Prof. Sebastien PAPOT
Targeting the Specificities of the Tumor Microenvironment for Cancer Therapy and Diagnosis (LE078)
Mr Carsten PEUKERT
DOTAM-based Sideromycins to Visualize and Treat MDR Bacterial Pathogens in vivo and in vitro (LE066)
Dr Davia PRISCHICH
In vivo Adrenergic Modulation with Photopharmacology (LE016)
Ms Jessica REYNOLDS
EFMC-YMCS Presentation Prize
Design and Synthesis of Chemical Tools to Probe the Function of TRIM33 (LE095)
Ms Suzanne Sherihan SAHRAOUI
Development of A New Target Identification System for Small Molecules in Trypanosoma Brucei Parasites (LE008)
Prof. Dennis SCHADE
Probing Embryonic Mesodermal Differentiation Enables Identification of Small Molecule Bone Morphogenetic Protein Activators (LE042)
Mr Frank SCHEFFLER
Integration of Biocatalysis into Medicinal Chemistry Programs for Late-Stage Oxidised Derivatives using Polycyps Enzymes (LE099)
Dr Duncan SHAW
Design and Development of Inhaled Molecules to Target the Pulmonary Vasculature (LE051)
Dr Julie SPICER
Toward a New Therapy for Immune-mediated Tissue Injury (LE079)
Dr James THOMPSON
Investigating the Chameleonic Properties of RGD Integrin Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis (LE090)